You are here » Home » Companies » Company Overview » Jubilant Life Sciences Ltd

Jubilant Life Sciences Ltd.

BSE: 530019 Sector: Health care
NSE: JUBILANT ISIN Code: INE700A01033
BSE LIVE 15:46 | 20 Nov 660.15 -15.75
(-2.33%)
OPEN

680.00

HIGH

680.00

LOW

653.00

NSE 15:55 | 20 Nov 659.65 -18.20
(-2.68%)
OPEN

676.70

HIGH

676.70

LOW

652.20

OPEN 680.00
PREVIOUS CLOSE 675.90
VOLUME 64386
52-Week high 879.10
52-Week low 552.40
P/E 92.85
Mkt Cap.(Rs cr) 10,516
Buy Price 660.15
Buy Qty 21.00
Sell Price 0.00
Sell Qty 0.00
OPEN 680.00
CLOSE 675.90
VOLUME 64386
52-Week high 879.10
52-Week low 552.40
P/E 92.85
Mkt Cap.(Rs cr) 10,516
Buy Price 660.15
Buy Qty 21.00
Sell Price 0.00
Sell Qty 0.00

Jubilant Life Sciences Ltd. (JUBILANT) - Company History

Jubilant Life Sciences Limited (JLSL) (formerly - Jubilant Organosys Limited) is an integrated pharmaceutical industry player having presence across the pharmaceuticals value chain. The Company was incorporated in 21st June of the year 1978 JLSL are a collaborative and innovative provider of products and services to the global life sciences industry striving to accelerate the process of pharmaceutical drug approval. The Company's range of offerings include drug discovery and development services custom research and manufacturing services advance intermediates fine chemicals active pharmaceutical ingredients dosage forms and regulatory affairs services. Its business is organized in three business segments namely Pharmaceuticals & Life Science Products Industrial Products and Performance Polymers. These businesses offer products and services to meet the demands of the Pharmaceuticals Agrochemicals Construction Food & Beverages Textile Tyres and Paper & Packaging industries. Over the years Jubilant Life Sciences has extended its footprint beyond India in the USA Canada Europe and other countries across the globe. We have also expanded the business by building capabilities internally through strategic expansions and acquisitions This resulted in a network of 7 world class manufacturing facilities in India and 5 in North America and a team of around 6100 multicultural people across the globe with 1200 in North America and 900 in R&D.The Company was tapped capital market in the year 1981 by the way of its Initial Public Offering (IPO). During the year 1983 the company's commercial production of Vinyl Acetate Monomer (VAM was started to enhance the value of the company. Research & Development center of the company got recognition from Government of India in the year 1985. JLSL had introduced new products in Performance Chemicals segments during the period of 1987 Poly vinyl acetate emulsion for paint textile paper & packaging and woodworking industry. In 1988 the company had launched its first branded product under the name of Vamicol an adhesive product. The plant for Pyridine & Picoline was started in the year 1990 and also the company received an ISO 9001 certification for its well known quality systems in the year 1995. During the year 1997 the first Multi-purpose fine chemicals plant was gone to stream and also the plant for food polymer was commissioned. After a year in 1998 JLSL had entered into high value-added Pyridine derivates commissioned Pyridine HBR and Cyano Pyridine plants. also in the same year the company had formed marketing subsidiary in the USA and acquired acetyl plant in western India. The Company had penetrated the Bio / chemo informatics arena by setting up Jubilant Biosys Ltd in the year 2000. During the year 2001 the company had changed its corporate and business profile due to this; the new corporate identity was born as Jubilant Life Sciences Ltd. JLSL had acquired the Active Pharmaceutical Ingredients (API) business in the period of 2002. The new state-of-the-art Research & Development Centre of the company in Noida near New Delhi was established in the year 2003 with all latest scientific instruments. The Company bagged Golden Peacock award for Innovation Management for the year 2003. During the year 2004 JLSL had set up medicinal chemistry services business through wholly owned subsidiary Jubilant Chemsys Ltd and also entered into formulations & regulatory affairs businesses by acquiring Pharmaceuticals Services. In the same year the company had incorporated N.V. and PSI Supply N.V. the pharmaceutical companies in Europe. JLSL had received C Acharya Award for Development of Indigenous Technology from ICMA for the year 2004. JLSL had acquired the Target Research Associates Inc in the year of 2005 and renamed Clinsys Inc.; a US based Clinical Research Organisation (CRO). Also in the same year the company had acquired Trinity Laboratories Inc. and its wholly owned subsidiary Trigen Laboratories Inc. renamed Jubilant Pharmaceuticals Inc. a generic pharmaceutical company in USA having a US FDA approved formulations manufacturing facility. JLSL had embarked into Clinsys business by setting up wholly owned subsidiary under the name and style of Jubilant Clinsys Ltd. Jubilant's state-of-the-art Drug Discovery facility was inaugurated in Bangalore during November of the year 2006 the largest of its kind in India for providing integrated Drug Discovery solutions. As of June 2007 JLSL had completed the largest overseas acquisition in Contract Manufacturing by an Indian company through its purchase of Hollister-Stier Laboratories (Hollister). A multi million dollar long term agreement was signed with Syngenta in September of the year 2007 for the supply of Pyridines. In December of the year 2007 the company and Forest Laboratories Holdings Ltd. a wholly owned subsidiary of Forest Laboratories Inc had entered into a collaboration agreement through Jubilant Biosys Ltd. a subsidiary of Jubilant Organosys Ltd to discover small molecule drug candidates for a novel metabolic disorders target. JLSL had completed the transaction effective May of the year 2008 to acquire Canada based Draxis Speciality Pharmaceuticals Inc. (Draxis) for US$ 253 million and also in the same month of the same year the company had acquired Speciality Molecules Pvt. Ltd. a niche manufacturer of Speciality Intermediates with manufacturing facilities located in Ambarnath (near Mumbai) in India for Rs. 199.5 million. The Company and Amgen Inc Thousand Oaks California the largest US based Biotech Company made a drug discovery partnership in July of the year 2008 through Jubilant Biosys Ltd subsidiary of Jubilant Organosys under which Amgen and Jubilant collaborate to develop a portfolio of novel drugs in new target areas of interest across multiple therapeutic areas.During the year 2009-10 In line with continued strategy of enhancing its focus as a Pharmaceuticals and Life sciences company the demerger of the Agri and Performance Polymer division into a separate company was approved in principle by the management on January 21 2010. The demerged entity is Jubilant Industries Ltd where as the name of Jubilant Organosys is changed to Jubilant Life Sciences Ltd.During the year 2011-12 the company set up global plants of Vitamin B3 and 3-Cyanopyridine at Special Economic Zone making it the largest producer of Vitamin B3 in India and scond largest globally. It is also setting up a manufacturing plant at SEZ for Symtet a crop science ingredient for one of the world's largest and safest low cost insecticide through an environment friently process.During the year 2013-14 The company sold its Hospital business to Narayana Health. The business has been transferred on a going concern basis as a slump sale which will enable it to focus on its core businesses in Pharmaceuticals and Life Sciences.In 2014-15 The company have completed the consolidation of all its Pharmaceutical business under Jubilant Pharma Singapore with effect from July 1 2014.